全文获取类型
收费全文 | 149933篇 |
免费 | 10465篇 |
国内免费 | 761篇 |
专业分类
耳鼻咽喉 | 1411篇 |
儿科学 | 3859篇 |
妇产科学 | 2741篇 |
基础医学 | 20014篇 |
口腔科学 | 3450篇 |
临床医学 | 14530篇 |
内科学 | 32064篇 |
皮肤病学 | 2874篇 |
神经病学 | 14525篇 |
特种医学 | 6101篇 |
外国民族医学 | 6篇 |
外科学 | 22856篇 |
综合类 | 1889篇 |
现状与发展 | 2篇 |
一般理论 | 139篇 |
预防医学 | 10752篇 |
眼科学 | 3176篇 |
药学 | 10434篇 |
中国医学 | 245篇 |
肿瘤学 | 10091篇 |
出版年
2023年 | 744篇 |
2022年 | 492篇 |
2021年 | 2530篇 |
2020年 | 1960篇 |
2019年 | 2818篇 |
2018年 | 3429篇 |
2017年 | 2666篇 |
2016年 | 3048篇 |
2015年 | 3517篇 |
2014年 | 5035篇 |
2013年 | 6801篇 |
2012年 | 10520篇 |
2011年 | 11143篇 |
2010年 | 6351篇 |
2009年 | 6045篇 |
2008年 | 10201篇 |
2007年 | 10878篇 |
2006年 | 10348篇 |
2005年 | 10596篇 |
2004年 | 10002篇 |
2003年 | 9485篇 |
2002年 | 8860篇 |
2001年 | 1453篇 |
2000年 | 1044篇 |
1999年 | 1442篇 |
1998年 | 1751篇 |
1997年 | 1361篇 |
1996年 | 1119篇 |
1995年 | 1250篇 |
1994年 | 1105篇 |
1993年 | 1077篇 |
1992年 | 752篇 |
1991年 | 774篇 |
1990年 | 602篇 |
1989年 | 583篇 |
1988年 | 543篇 |
1987年 | 557篇 |
1986年 | 493篇 |
1985年 | 525篇 |
1984年 | 620篇 |
1983年 | 547篇 |
1982年 | 751篇 |
1981年 | 686篇 |
1980年 | 587篇 |
1979年 | 350篇 |
1978年 | 363篇 |
1977年 | 390篇 |
1976年 | 325篇 |
1975年 | 283篇 |
1974年 | 249篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
Streibert Fridolin Bernhardt Claudia Simon Philipp Hilbert-Carius Peter Wrigge Hermann 《Der Anaesthesist》2023,72(1):57-62
Die Anaesthesiologie - Die Anlage einer Magensonde im OP oder auf einer Intensivstation (ITS) stellt eine alltäglich durchgeführte Prozedur dar. Obwohl die Sonde häufig durch... 相似文献
14.
Peter H. Egbers Anna-Liisa Sutt Jenny E. Petersson Liza Bergström Eva Sundman 《Acta anaesthesiologica Scandinavica》2023,67(10):1403-1413
Background
Weaning from mechanical ventilation and tracheostomy after prolonged intensive care consume enormous resources with optimal management not currently well described. Restoration of respiratory flow via the upper airway is essential and early cuff-deflation using a one-way valve (OWV) is recommended. However, extended OWV use may cause dry airways and thickened secretions which challenge the weaning process. High-flow therapy via the tracheostomy tube (HFT-T) humidifies inspired air and may be connected via an in-line OWV (HFT-T-OWV) alleviating these problems. We aim to provide clinical and experimental data on the safety of HFT-T-OWV along with a practical guide to facilitate clinical use during weaning from mechanical ventilation and tracheostomy.Methods
Data on adverse events of HFT-T-OWV were retrieved from a quality register for patients treated at an intensive care rehabilitation center between 2019 and 2022. Benchtop experiments were performed to measure maximum pressures and pressure support generated by HFT-T-OWV at 25–60 L/min flow using two different HFT-T adapters (interfaces). In simulated airway obstruction using a standard OWV (not in-line) maximum pressures were measured with oxygen delivered via the side port at 1–3 L/min.Results
Of 128 tracheostomized patients who underwent weaning attempts, 124 were treated with HFT-T-OWV. The therapy was well tolerated, and no adverse events related to the practice were detected. The main reason for not using HFT-T-OWV was partial upper airway obstruction using a OWV. Benchtop experiments demonstrated HFT-T-OWV maximum pressures <4 cmH2O and pressure support 0–0.6 cmH2O. In contrast, 1–3 L/min supplemental oxygen via a standard OWV caused pressures between 84 and 148 cmH2O during simulated airway obstruction.Conclusions
Current study clinical data and benchtop experiments indicate that HFT-T-OWV was well tolerated and appeared safe. Pressure support was low, but humidification may enable extended use of a OWV without dry airway mucosa and thickened secretions. Results suggest the treatment could offer advantages to standard OWV use, with or without supplementary oxygen, as well as to HFT-T without a OWV, for weaning from mechanical ventilation and tracheostomy. However, for definitive treatment recommendations, randomized clinical trials are needed. 相似文献15.
16.
17.
18.
Bielik Peter Bonczek Ondřej Krejčí Přemysl Zeman Tomáš Izakovičová-Hollá Lydie Šoukalová Jana Vaněk Jiří Vojtěšek Bořivoj Lochman Jan Balcar Vladimir J. Šerý Omar 《Clinical oral investigations》2022,26(12):7045-7055
Clinical Oral Investigations - The aim of this study was the analysis of WNT10A variants in seven families of probands with various forms of tooth agenesis and self-reported family history of... 相似文献
19.
Raya Saab MD Anas Obeid MD Fatiha Gachi MD Houda Boudiaf MD Lilit Sargsyan MD Khulood Al-Saad MD Tamar Javakhadze MD Azim Mehrvar MD Sawsan Sati Abbas MD Yasir Saadoon Abed Al-Agele MD Salma Al-Haddad MD Mouroge Hashim Al Ani MD Suleiman Al-Sweedan MD Amani Al Kofide MD Wasil Jastaniah MD Nisreen Khalifa MD Elie Bechara MD Malek Baassiri MD Peter Noun MD Jamila El-Houdzi MD Mohammed Khattab MD Krishna Sagar Sharma MD Yasser Wali MD Naureen Mushtaq MD Aliya Batool MD Mahwish Faizan MD Muhammad Rafie Raza MD Mohammad Najajreh MD Mohammed Awad Mohammed Abdallah MD Ghada Sousan MD Khaled M. Ghanem MD Ulker Kocak MD Tezer Kutluk MD Hacı Ahmet Demir MD Hamoud Hodeish MD Samar Muwakkit MD Asim Belgaumi MD Abdul-Hakim Al-Rawas MD Sima Jeha MD 《Cancer》2020,126(18):4235-4245
20.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献